Best of ASCO - 2014 Annual Meeting

 

Welcome

Hepatobiliary Cancer

Gastrointestinal (Noncolorectal) Cancer

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A MRI-based radiomics model for preoperative prediction of five-year survival status in hepatocellular carcinoma.

Xiao-Hang Wang

e15596

A multi-center phase Ib/II study of nal-irinotecan, 5-fluouracil and leucovorin in combination with nivolumab as second-line therapy for patients with advanced unresectable biliary tract cancer.

Vaibhav Sahai

TPS4154

A multicenter phase II trial of rucaparib in combination with nivolumab as maintenance therapy for patients with advanced biliary tract cancer.

Vaibhav Sahai

TPS4153

A multicenter randomized controlled trial to evaluate the efficacy of surgery vs. radiofrequency ablation for small hepatocellular carcinoma (SURF trial).

Namiki Izumi

4002

A novel preclinical model of cholangiocarcinoma based on human aberrant FBXW7 expression.

Jingxiao Wang

e15624

A novel subpopulation of circulating tumor cells in patients with cholangiocarcinoma.

Carolina Reduzzi

e15637

A phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) patients (pts).

Teresa Macarulla Mercade

4095

A phase II study of anti–PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer.

Shukui Qin

4074

A phase II study of nivolumab in patients with advanced refractory biliary tract cancers (BTC).

Richard D. Kim

4097

A retrospective analysis of clinical outcomes among patients with infiltrative hepatocellular carcinoma (iHCC): A single institution study.

Lindsay Marie Hannan

e15667

ABC-06 | A randomised phase III, multi-centre, open-label study of Active Symptom Control (ASC) alone or ASC with oxaliplatin / 5-FU chemotherapy (ASC+mFOLFOX) for patients (pts) with locally advanced / metastatic biliary tract cancers (ABC) previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.

Angela Lamarca

4003

Additional prognostic value of metabolic parameters measured by dual time point pretreatment F-18 FDG PET/CT in patients with intrahepatic cholangiocarcinoma.

Jae Pil Hwang

e15598

An exploratory analysis based on tumor location of REACHIN, a randomized double-blinded placebo-controlled phase II trial of regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced (nonresectable) and metastatic biliary tract tumors.

Anne Demols

e15622

Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.

Ghassan K. Abou-Alfa

4088

Association of liver-directed local therapy with overall survival in metastatic intrahepatic cholangiocarcinoma.

Nikhil Sebastian

e15659

Association of the ratio of CD8+ and CD163+ lymphocytes with clinical outcome in hepatocellular carcinoma.

Huan Chen

e15613

Can artificial intelligence support the clinical decision making for Barcelona clinic liver cancer stage 0/a hepatocellular carcinoma in China?

Ze-bin Chen

e15634

Cell-free junctional DNA fragment from hepatitis B virus integration in HCC for monitoring postresection recurrence and clonality.

Ya-Chun Wang

4090

Characterization of tumor mutation burden, PD-L1 and hepatitis B virus in Chinese hepatocellular carcinoma patients.

Junjie Xu

e15666

Characterizing PD-L1/PD-1 expression in hepatocellular carcinoma and implications on postresection treatment response.

Mark Farha

e15626

Chemotherapy (CT) or chemoradiation (CTRT) in postoperative (simple cholecystectomy) carcinoma gall bladder (GBC) with residual disease, unsuitable for revision surgery.

Sushma Agrawal

e15594

Chromosome 8q24 amplification predicts prognosis for patients with advanced hepatocellular carcinoma (HCC).

Yuan Cheng

e15654

Chronotherapeutic regimen with liposomal cisplatin for systemic treatment of primary liver cancer.

Levan Tavartkiladze

e15678

Clinical and molecular features of patients with cholangiocarcinoma harboring FGFR genetic alterations.

Alice Boileve

4084

Clinical and prognostic significance of serum levels of fatty acid binding proteins in hepatocellular carcinoma (HCC).

Yehia I. Abugabal

4099

Clinical predictors of radiographic progression of a hepatic lesion from Li-RADS 3 to Li-RADS 5 among a population of individuals at high risk of hepatocellular carcinoma.

Lindsay Marie Hannan

e15668

Combinational strategies of immunotherapy for hepatocellular carcinoma: One institutional experience in Taiwan.

Jo-Pai Chen

e15684

Comprehensive genomic profiling in FIGHT-202 reveals the landscape of actionable alterations in advanced cholangiocarcinoma.

Ian M. Silverman

4080

CT-based radiogenomic signature to identify isocitrate dehydrogenase (IDH)1/2 mutations in advanced intrahepatic cholangiocarcinoma.

Tagwa Idris

4081

Density of CD8+ and CD68+ lymphocyte cell infiltration is associated with clinic outcome in hepatocellular carcinoma.

Haibei Xin

e15612

Derazantinib (DZB) provides antitumor efficacy regardless of line of therapy in patients (pts) with FGFR2-fusion positive advanced intrahepatic cholangiocarcinoma (iCCA).

Michele Droz Dit Busset

e15607

Development of radiotherapeutic rhenium-188 liposomes in alginate microspheres (Rhe-LAMs) for treatment of liver tumors and technetium-99m liposomes in alginate microspheres (Tech-LAMs) for image-guided treatment planning.

Ryan D. Bitar

e15599

DNA damage repair (DDR) gene alterations as a predictive biomarker for response to platinum-containing chemotherapy in advanced biliary tract cancer (BTC).

Heejung Chae

4078

Dose-survival relationship in patients with hepatocellular carcinoma undergoing stereotactic body radiation therapy.

Ting-Shi Su

e15592

Dynamic changes in the immune infiltrate within hepatocellular carcinoma tumor correlate with response to PD-1 blockade.

Thomas Urban Marron

e15644

Effect of cholangitis on pre-operative evaluation of regional lymphadenopathy by CT in pancreato-biliary malignancies.

Abhijit Chandra

e15651

Efficacy and safety of FOLFIRINOX in advanced biliary tract cancer after failure of gemcitabine plus cisplatin: A phase II trial.

Ali Belkouz

4086

Efficacy and safety of pembrolizumab in patients with PD-L1 positive advanced biliary tract cancer (BTC): A prospective cohort study.

Junho Kang

4082

Epidemiology, prevalence and national trends of combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CCA) in hospitalized US patients between 2002-2014.

Ahmed Elkafrawy

e15616

ET140202 t-cells: A novel therapy targeting AFP/MHC complex, that is both safe and effective in treating metastatic hepatocellular carcinoma.

Chang Liu

e15614

Expression and heterodimerization of Type A and B Cholecystokinin Receptors in Gallbladder cancer.

Abhijit Chandra

e15655

Final analysis of phase II trial of regorafenib (REG) in refractory advanced biliary cancers (BC).

Dae Won Kim

4083

First-in-class hafnium oxide nanoparticles NBTXR3 in the treatment of liver cancers.

Enrique Chajon

e15642

First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).

Masatoshi Kudo

4072

FOXO1, an AKT downstream substrate, plays a role as tumor suppressor in HCC pathogenesis.

Shu Zhang

e15627

Frequency of BRCA mutation in biliary tract cancer and its correlation with tumor mutational burden (TMB) and microsatellite instability (MSI).

Gilbert Spizzo

4085

Functional personalized oncology to determine drug sensitivity in cholangiocarcinoma.

Ali Zarrinpar

e15672

Genomic analysis of hepatocellular carcinoma (HCC) with active hepatitis B virus (HBV) replication.

Huat Chye Lim

e15593

Genomic landscape of HBV-related hepatocellular carcinoma in south China patients with high mutational frequency of TP53 and TERT promoter.

Jiazhou Ye

e15670

Health-related quality-of-life in patients with cholangiocarcinoma: Results of a systematic literature review.

Yohan Cho

e15623

Hepatocellular carcinoma with tumor thrombus in portal vein branch: Transarterial chemoembolization combined with Iodine125 brachytherapy versus transarterial chemoembolization combined with sorafenib.

Jingjun Huang

e15646

High spatiotemporal heterogeneity, clonal selection and neoantigen evolution in acquired sorafenib-resistant patient-derived xenograft models of hepatocellular carcinoma.

Xin-Rong Yang

e15641

Histone deacetylase 6-EGFR axis in recurrent hepatocellular carcinoma.

Yao-Tsung Yeh

e15638

HIV associated hepatocellular cancer (HCC) in an inner-city minority population.

V V Pavan Kedar Mukthinuthalapati

e15680

Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced hepatocellular carcinoma.

Mao Li

e15606

IGF-Child-Pugh score as a predictor of treatment outcome in advanced hepatocellular carcinoma patients treated with sorafenib.

Yehia I. Abugabal

4076

Imaging biomarker phenotyping system (iBiopsy) to accelerate hepatocellular carcinoma (HCC) drug development.

Yan Liu

e15671

Impact of HCV treatment in patients with advanced hepatocellular carcinoma on sorafenib.

Michael Herman

e15645

Impact of tumor shrinkage pattern by biweekly triplet gemcitabine/cisplatin/s-1 for biliary tract cancers: Implication for neoadjuvant therapy (KHBO1401-1A study).

Shogo Kobayashi

4093

Impact on gemcitabine plus cisplatin in unresectable hilar cholangiocarcinoma patients according to effective biliary drainage: A multicenter study.

Jingu Kang

e15658

Improved survival following transarterial radioembolization of infiltrative-appearance hepatocellular carcinoma.

Michael J Nisiewicz

e15591

Infigratinib versus gemcitabine plus cisplatin multicenter, open-label, randomized, phase 3 study in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: The PROOF trial.

Milind M. Javle

TPS4155

Integrated multi-omic analysis to reveal comprehensive tumor heterogeneity and novel immunophenotypic classification in primary liver cancer.

Qi Zhang

e15662

Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.

Josep M Llovet

TPS4152

Lenvatinib for the treatment of HCC: A single institute experience.

San-Chi Chen

e15611

Liver resection in elderly patients over the age of 70 with primary liver cancer: A retrospective analysis.

Elinor Tan

e15647

Microvascular invasion may guide selection of candidates for combination treatment with sorafenib and TACE for intermediate recurrent hepatocellular carcinoma.

Zhen-Wei Peng

e15601

Molecular differences between AFP-negative and AFP-positive hepatocellular carcinoma.

Wu yu Ling

e15681

Molecular pathway activation-based analysis for personalized prescription of tyrosine kinase inhibitors for advanced solid tumor patients.

Elena Poddubskaya

e15636

Molecular profiling by circulating tumor DNA (ctDNA) and benefit from anti-PD-1 in HCC.

Roberto Carmagnani Pestana

e15679

Multicentric prospettive study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: Interim analysis of INNOVATE study.

Andrea Casadei Gardini

4075

Mutation profiles in circulating tumor DNA (ctDNA) to predict the efficacy of sorafenib treatment in patients with advanced hepatocellular carcinoma (HCC).

Ping Yang

e15648

Myopenia as a significant prognostic factor in BCLC-B intermediate-stage hepatocellular carcinoma treated with sorafenib.

Mao Okada

e15639

Nab-paclitaxel plus S-1 as first line treatment for advanced or metastatic biliary tract adenocarcinoma: A phase 2 study.

Yongkun Sun

4089

Nemesis: Non-inferiority meta-analysis of selective internal radiation therapy with yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular carcinoma: A preliminary analysis.

Marino Venerito

e15604

Neutrophil/lymphocyte ratio (NLR) may predict prognostic factor with gemcitabine/cisplatin/S-1 (GCS) for patients with advanced biliary tract cancer (MITSUBA /KHBO1401-1B).

Toru Otsuru

e15656

Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.

Thomas Yau

4012

Nivolumab for hepatocellular carcinoma (HCC) in a real-world context.

Nisha Rao

e15675

Non-invasive detection of acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations.

Anna M. Varghese

4096

Novel staging system using carbohydrate antigen (CA) 19-9 in extrahepatic cholangiocarcinoma (ECCC) and its implications on overall survival (OS).

Sri Harsha Tella

4091

NUC-1031 in combination with cisplatin for first-line treatment of advanced biliary tract cancer.

Jennifer J. Knox

TPS4156

Outcomes and patterns of failures after hypofractionated radiation therapy for intrahepatic cholangiocarcinoma.

Ibrahim Abu-Gheida

e15609

Outcomes of treatment of carcinoma gall bladder undergoing curative intent surgery.

Arun Chaturvedi

e15621

Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies.

Yung-Jue Bang

4079

Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy.

Robin Kate Kelley

TPS4157

Postsurgical multiple-sites sampling procedure for the precise detection of microvascular invasion of hepatocellular carcinoma.

Qian Zhou

e15657

Prediction of hepatocellular carcinoma patient survival using machine learning classification rules.

Wei Zhou

e15649

Predictors of poor outcome for transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC).

Petra Prins

4100

Profiling of 3,634 cholangiocarcinomas (CCA) to identify genomic alterations (GA), tumor mutational burden (TMB), and genomic loss of heterozygosity (gLOH).

Milind M. Javle

4087

Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).

Josep M Llovet

4073

Randomized clinical trial of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial chemoembolization for hepatocellular carcinoma with intermediate stage (BCLC stage B) hepatocellular carcinoma beyond Milan criteria.

Xin Yin

4077

Randomized phase II trial of sorafenib, capecitabine, and oxaliplatin (SECOX) versus single agent sorafenib in patients with advanced hepatocellular carcinoma.

Gin Wai Kwok

e15630

Randomized, open-label, perioperative phase II study evaluating nivolumab alone or nivolumab plus ipilimumab in patients with resectable HCC.

Ahmed Omar Kaseb

4098

Retrospective analysis of outcomes in patients with non metastatic cholangiocarcinoma: A single network experience.

Jyothika Mamadgi

e15643

Retrospective analysis of outcomes with different adjuvant treatments in cholangiocarcinoma: An NCDB review.

Jyothika Mamadgi

e15677

RISE-HEP project part 1: Treatment sequences evaluation in hepatocellular carcinoma cell lines.

Luca Faloppi

e15663

SHR-1210 plus GEMOX as first line treatment in biliary tract cancer: Results from a single-arm exploratory study.

Xiaofeng Chen

4092

The characterization of ERBB family mutations in Chinese biliary tract cancers.

Tianqiang Song

e15595

The combination of the NT157 and sorafenib as a new therapeutic option for hepatocellular carcinoma.

Hui Guo

e15610

The combined treatment of 150 kHz tumor treating fields (TTFields) and sorafenib inhibits hepatocellular carcinoma in vitro and in vivo.

Uri Weinberg

e15653

The effect of race on adherence to NCCN Guidelines for patients with biliary tract cancers (BTC) after surgery.

Asrar Alahmadi

e15686

The efficacy and safety of lenvatinib in patients who did not meet the inclusion criteria of the phase 3 trial (REFLECT trial) in real-world practice in Japan: A nationwide multicenter study in Japan.

Kaoru Tsuchiya

e15629

The heterogeneity of genomic biomarkers for immune checkpoint inhibitor in therapy-naïve primary hepatocellular carcinoma and their metachronous metastases.

Yun-Fan Sun

e15665

The impact of geography and center volume on access to care and outcomes in advanced hepatocellular carcinoma (HCC): A retrospective population based study.

Irene S. Yu

e15597

The impact of sorafenib on the treatment and survival of advanced hepatocellular carcinoma (HCC): Analysis of the National Cancer Database (NCDB) from 2004 to 2014.

Aman Opneja

e15682

The prognostic role of soluble transforming growth factor-β related with soluble programmed death-ligand 1 in biliary tract cancer.

Jin Won Kim

4094

Transcriptional characterization of microenvironment and their prediction role for the prognosis of hepatocellular carcinoma after surgery.

Kehe Chen

e15650

Trends from NSQIP 2015 to 2017 in neoadjuvant therapy use before pancreatic adenocarcinoma resection.

Rebecca C Gologorsky

e15685

Tumor mutation burden in biliary tract cancers with ERBB family or DNA damage repair gene mutations.

Yongjie Zhang

e15602

Tumor size and location affecting the treatment selection for solitary small recurrent hepatocellular carcinoma (≤3.0 cm) after initial hepatectomy.

Shu-Ling Chen

e15660

Use of DNA methylation to distinguish gallbladder carcinoma.

Xiaoqing Jiang

e15605